in a nutshell per MIchael Morrissey, "increasing the value of .....this emerging franchise around the drug (Cabozintinib). So that's the goal, that’s the logic. I think it makes sense and again we’re focused on getting this done with the great deal of urgency and energy. So again we’re all about cabozantinib, we’re all about COMETRIQ that’s how we’re spending our time and our money. Beyond that we have a rich pipeline of partnered compounds that were the result of our previous efforts in a large-scale level of drug discovery, early development. These are all compounds that we've discovered ourselves." To me, throughout the presentation, Morrissey sounded pretty enthusiastic and fired up for wide-scale success of Cabo.
They have enough cash in hand ($675M) and now will have at least $5M-$7M coming in every year from selling Cabo for MTC patients (500-700 a year, @ $9,900 per patient), not counting global demand! The top line results for COMET-1 and COMET-2 expected in 2014. Then, on to adding prostate cancer patients to the Cabo's clinical use roaster. I think the company is on to some real great success come 2014; i.e., a year from now and an excellent opportunity for investment at each dip in the share price.
"Morrissey sounded fired up for wide-scale success of Cabo."
LOL...ummmm, were you expecting anything less? He's on a road show.
People love to mention "all the cash on hand" but conveniently forget to mention the massive amount of DEBT they have to pay. Deerfield and the converts. Do some research. Look for the company to do another offering.
GL. GS remains in complete control as EXEL is a wide open book for them. There is zero risk for GS here. $$$$$$$$$$$
Oh, Morrissey also sounded like the company wants go all alone in this Cabo endeavor! No chance for a merger with a big pharma! And that is what the traders were looking for to hear from him and, alas! they have started selling off!! That creates a nice opportunity for us longs to accumulate more.